Bone Biologics Corporation
BBLG
$2.16
-$0.04-1.82%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -9.50% | 36.52% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -27.96% | -33.21% | |||
| Operating Income | 27.96% | 33.21% | |||
| Income Before Tax | 27.19% | 33.16% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 27.19% | 33.16% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 27.19% | 33.16% | |||
| EBIT | 27.96% | 33.21% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 30.75% | 47.93% | |||
| Normalized Basic EPS | 30.75% | 47.92% | |||
| EPS Diluted | 30.75% | 47.93% | |||
| Normalized Diluted EPS | 30.75% | 47.92% | |||
| Average Basic Shares Outstanding | 5.15% | 28.36% | |||
| Average Diluted Shares Outstanding | 5.15% | 28.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||